MRSN Stock Price, Mersana Therapeutics Inc Quote, Chart

Market Summary

USD2.63-0.08

Market Closed

-2.95%

MRSN Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

MRSN Stock Price

View Fullscreen

MRSN RSI Chart

MRSN Valuation

Market Cap

321.8M

Price/Earnings (Trailing)

-2.39

Price/Sales (Trailing)

8.4

Price/Free Cashflow

-1.85

MRSN Price/Sales (Trailing)

MRSN Profitability

Return on Equity

-481.73%

Return on Assets

-67.96%

Free Cashflow Yield

-54.05%

MRSN Fundamentals

MRSN Revenue

Revenue (TTM)

38.3M

Rev. Growth (Yr)

-27.14%

Rev. Growth (Qtr)

39.01%

MRSN Earnings

Earnings (TTM)

-134.8M

Earnings Growth (Yr)

65.63%

Earnings Growth (Qtr)

1.22%

Breaking Down MRSN Revenue

Last 7 days

-24.9%

Last 30 days

-31.0%

Last 90 days

-31.3%

Trailing 12 Months

-67.2%

How does MRSN drawdown profile look like?

MRSN Financial Health

Current Ratio

3.51

Debt/Equity

0.71

Debt/Cashflow

-8.72

MRSN Investor Care

Shares Dilution (1Y)

6.97%

Diluted EPS (TTM)

-1.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	38.3M	0	0	0
2023	32.3M	38.7M	40.8M	36.9M
2022	4.5M	8.2M	11.9M	26.6M
2020	0	28.4M	14.6M	828.0K
2019	48.6M	44.6M	43.3M	42.1M
2018	16.3M	16.8M	12.7M	10.6M
2017	25.8M	23.3M	26.3M	17.5M
2016	14.1M	17.8M	21.5M	25.2M
2015	0	0	0	10.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Mersana Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 16, 2024	lowinger timothy b	sold	-28,208	2.71	-10,409	svp, chief sci.&tech. officer
Jan 16, 2024	misra tushar	sold	-9,097	2.71	-3,357	svp, chief manuf. officer
Jan 16, 2024	deschuytner brian	sold	-25,276	2.71	-9,327	svp, coo & cfo
Jan 16, 2024	bala mohan	sold	-9,298	2.71	-3,431	svp, chief development officer
Jan 16, 2024	mandelia ashish	sold	-13,617	2.71	-5,025	vp, chief accounting officer
Jan 16, 2024	protopapas anna	sold	-79,671	2.71	-29,399	-
Jan 16, 2024	carvajal alejandra	sold	-11,872	2.71	-4,381	svp, chief legal officer
Jan 15, 2024	protopapas anna	acquired	-	-	38,958	-
Jan 15, 2024	lowinger timothy b	acquired	-	-	15,208	svp, chief sci.&tech. officer
Jan 15, 2024	mandelia ashish	acquired	-	-	5,352	vp, chief accounting officer

Which funds bought or sold MRSN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-1.49	8,029	16,920	-%
May 10, 2024	LPL Financial LLC	sold off	-100	-177,930	-	-%
May 10, 2024	BlackRock Inc.	added	3.21	18,070,100	36,268,900	-%
May 10, 2024	GROUP ONE TRADING, L.P.	sold off	-100	-72,108	-	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	22.04	97,032	168,560	-%
May 10, 2024	VANGUARD GROUP INC	added	0.59	13,638,000	28,109,200	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	added	166	1,692,000	2,099,000	0.01%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	reduced	-69.27	-95,921	139,969	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	7,688	7,688	-%
May 10, 2024	PNC Financial Services Group, Inc.	unchanged	-	432	896	-%

Are Funds Buying or Selling MRSN?

Are funds buying MRSN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRSN

No. of Funds

Unveiling Mersana Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	silverarc capital management, llc	5.3%	6,420,136	SC 13G
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	9.4%	11,328,000	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	0%	0	SC 13G/A
Feb 14, 2024	balyasny asset management l.p.	8.04%	9,698,147	SC 13G
Feb 14, 2024	orbimed advisors llc	0.0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	5.17%	6,237,588	SC 13G
Jan 29, 2024	blackrock inc.	6.5%	7,844,282	SC 13G/A
Jan 22, 2024	state street corp	1.93%	2,329,434	SC 13G/A
Aug 07, 2023	venrock healthcare capital partners iii, l.p.	8.5%	9,678,000	SC 13G
Jul 27, 2023	ecor1 capital, llc	16.9%	19,364,688	SC 13G

Recent SEC filings of Mersana Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	EFFECT	EFFECT
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	424B5	Prospectus Filed
May 09, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Feb 28, 2024	8-K	Current Report
Feb 28, 2024	10-K	Annual Report

Peers (Alternatives to Mersana Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Mersana Therapeutics Inc News

Latest updates

Mersana Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2020Q4	2020Q3	2020Q2	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	-13.6%	9,245	10,701	7,698	10,654	7,802	14,688	5,573	4,284	2,036	11.00	21.00	32.00	42.00	844	202	41,035	1,189	2,151	4,191	3,064	3,261
Operating Expenses	-5.9%	30,246	32,128	51,639	67,155	65,603	60,514	65,212	56,034	48,588	28,772	22,427	20,584	16,642	18,137	17,958	19,586	23,968	19,560	16,894	-	-
S&GA Expenses	-100.0%	-	10,134	12,894	18,187	18,328	14,805	14,573	14,803	12,782	5,914	5,881	5,171	4,212	4,436	4,192	4,443	4,152	4,380	4,231	3,571	-
R&D Expenses	-13.1%	18,686	21,495	30,531	48,968	47,275	45,709	50,639	41,231	35,806	22,858	16,546	15,413	12,430	13,701	13,766	15,143	19,816	15,180	12,663	-	-
Interest Expenses	-4.4%	1,002	1,048	1,017	1,025	983	964	880	760	724	92.00	92.00	87.00	87.00	107	40.00	-	-	-	-	-	-
Net Income	1.2%	-19,306	-19,544	-41,656	-54,307	-56,163	-44,918	-59,811	-52,219	-47,258	-28,844	-22,489	-19,786	-16,246	-16,792	-17,071	21,901	-22,431	-17,069	-12,354	-	-
Net Income Margin	24.4%	-3.52*	-4.66*	-4.82*	-5.56*	-6.59*	-7.68*	-17.49*	-23.61*	-40.40*	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-1.4%	-32,789	-32,348	-46,553	-62,233	-29,916	-52,014	54,171	-45,433	-8,284	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-12.2%	198	226	263	311	296	334	315	252	258	206	218	254	248	273	290	311	96.00	108	122	139	149
Current Assets	-12.4%	188	214	250	297	282	319	300	237	241	189	199	233	232	259	275	295	80.00	101	115	132	141
Cash Equivalents	-56.7%	76.00	175	186	129	123	129	184	135	230	178	192	227	228	255	271	288	60.00	63.00	58.00	116	137
Net PPE	-	-	-	-	-	-	4.00	-	-	-	2.00	-	-	-	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00
Liabilities	-9.9%	170	189	211	221	232	242	225	118	118	84.00	62.00	58.00	50.00	45.00	37.00	37.00	33.00	29.00	29.00	31.00	25.00
Current Liabilities	-16.1%	53.00	64.00	68.00	75.00	83.00	92.00	89.00	71.00	56.00	48.00	44.00	40.00	35.00	30.00	21.00	22.00	17.00	24.00	22.00	24.00	23.00
Short Term Borrowings	-100.0%	-	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-14.5%	20.00	23.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	5.00	5.00	5.00	5.00	5.00	3.00	4.00	4.00	5.00	5.00	-
LT Debt, Current	150.0%	5.00	2.00	-	-	-	-	-	-	-	-	-	0.00	-	-	-	2.00	1.00	1.00	0.00	-	-
LT Debt, Non Current	-100.0%	-	23.00	-	-	-	25.00	-	-	-	25.00	-	-	-	5.00	5.00	3.00	4.00	4.00	5.00	5.00	-
Shareholder's Equity	-24.2%	28.00	37.00	52.00	90.00	64.00	92.00	90.00	134	141	122	156	196	198	228	253	274	63.00	78.00	93.00	109	124
Retained Earnings	-2.3%	-845	-826	-806	-765	-710	-654	-609	-549	-497	-450	-401	-356	-315	-280	-251	-229	-209	-192	-176	-159	-142
Additional Paid-In Capital	1.2%	874	863	859	855	775	747	700	684	638	572	557	552	513	508	505	503	272	271	269	268	266
Shares Outstanding	1.4%	122	121	121	120	109	105	91.00	96.00	80.00	71.00	70.00	69.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	364	-	-	-	403	-	-	-	800	-	-	-	1,148	-	-	-	164	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-2.2%	-32,657	-31,962	-46,081	-61,834	-29,005	-51,229	54,597	-44,776	-7,955	-42,400	-36,098	-34,468	-27,022	-17,319	-20,196	-15,935	-21,246	-12,576	-16,284	-14,197	-24,687
Share Based Compensation	14.1%	4,660	4,085	4,001	6,643	6,407	5,314	5,375	5,348	5,485	4,860	4,928	4,582	4,039	1,989	1,918	1,656	1,609	1,262	1,285	1,161	1,164
Cashflow From Investing	-460.1%	-72,547	20,148	103,778	-5,439	1,396	-45,426	-16,491	-90,470	-329	-155	-46.00	-333	-114	-188	2,805	14,975	19,435	16,500	-41,768	-12,153	10,128
Cashflow From Financing	6235.9%	5,829	92.00	-146	73,180	21,549	41,458	10,638	40,527	60,394	28,795	463	33,916	472	1,665	-49.00	228,886	-90.00	231	-8.00	5,277	92,204

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MRSN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Collaboration revenue	$ 36,855	$ 26,581	$ 43
Operating expenses:
Research and development	148,269	173,385	132,013
General and administrative	59,543	56,963	36,888
Restructuring expenses	8,713	0	0
Total operating expenses	216,525	230,348	168,901
Other income (expense):
Interest income	12,073	2,883	65
Interest expense	(4,073)	(3,328)	(1,267)
Total other income (expense), net	8,000	(445)	(1,202)
Net loss	(171,670)	(204,212)	(170,060)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	163	(152)	0
Comprehensive loss	(171,507)	(204,364)	(170,060)
Net loss attributable to common stockholders - basic	(171,670)	(204,212)	(170,060)
Net loss attributable to common stockholders - diluted	$ (171,670)	$ (204,212)	$ (170,060)
Net loss per share attributable to common stockholders — basic (in dollars per share)	$ (1.48)	$ (2.18)	$ (2.41)
Net loss per share attributable to common stockholders — diluted (in dollars per share)	$ (1.48)	$ (2.18)	$ (2.41)
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic (in shares)	116,112,891	93,654,243	70,580,949
Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — diluted (in shares)	116,112,891	93,654,243	70,580,949

MRSN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 174,561	$ 128,885
Short-term marketable securities	34,523	151,827
Accounts receivable	0	30,000
Prepaid expenses and other current assets	4,973	8,507
Total current assets	214,057	319,219
Property and equipment, net	3,831	3,985
Operating lease right-of-use assets	7,694	10,475
Other assets, noncurrent	478	661
Total assets	226,060	334,340
Current liabilities:
Accounts payable	7,319	13,951
Accrued expenses	21,898	43,184
Deferred revenue	28,147	30,610
Operating lease liabilities	3,252	2,798
Short-term debt	2,083	0
Other current liabilities	938	990
Total current liabilities	63,637	91,533
Operating lease liabilities, noncurrent	5,149	8,575
Long-term debt, net	23,148	24,929
Deferred revenue, noncurrent	97,167	117,043
Other liabilities, noncurrent	55	203
Total liabilities	189,156	242,283
Commitments (Note 15)
Stockholders' equity
Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	0	0
Common stock, $0.0001 par value; 350,000,000 shares authorized; 120,711,745 and 105,144,864 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	12	11
Additional paid-in capital	863,242	746,889
Accumulated other comprehensive income (loss)	11	(152)
Accumulated deficit	(826,361)	(654,691)
Total stockholders’ equity	36,904	92,057
Total liabilities and stockholders’ equity	$ 226,060	$ 334,340
Common stock, shares authorized (in shares)	350,000,000	350,000,000

About Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Martin H. Huber Jr., M.D.
WEBSITE	mersana.com
INDUSTRY	Biotechnology
EMPLOYEES	228

Mersana Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Mersana Therapeutics Inc? What does MRSN stand for in stocks?

MRSN is the stock ticker symbol of Mersana Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mersana Therapeutics Inc (MRSN)?

As of Mon May 13 2024, market cap of Mersana Therapeutics Inc is 321.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRSN stock?

You can check MRSN's fair value in chart for subscribers.

What is the fair value of MRSN stock?

You can check MRSN's fair value in chart for subscribers. The fair value of Mersana Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Mersana Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRSN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Mersana Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MRSN is over valued or under valued. Whether Mersana Therapeutics Inc is cheap or expensive depends on the assumptions which impact Mersana Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRSN.

What is Mersana Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, MRSN's PE ratio (Price to Earnings) is -2.39 and Price to Sales (PS) ratio is 8.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRSN PE ratio will change depending on the future growth rate expectations of investors.